PMID: 6968854Jan 1, 1980Paper

Characterization of in vivo suppression of syngenic tumor by allogenic effector cells

Journal of Surgical Oncology
P H SugarbakerP P Pun

Abstract

The purpose of this study was to characterize the effects of allogenic splenocytes transferred with tumor cells, subcutaneously, to a host syngenic for tumor cells. Cytotoxic effector cells usually resulted in tumors less than half the size of controls at E:T of 10:1. Primary immune splenocytes were more effective than hyperimmune splenocytes in delaying tumor growth. Actively cytotoxic splenocytes by in vitro 51Cr release assay were required for delayed tumor growth; memory cell populations were not effective. Delayed tumor growth correlated with in vitro cytotoxicity of primary immune splenocytes; however, hyperimmune splenocytes, even though they possessed greater in vitro cytotoxic responses, showed lesser tumor suppression in vivo. T cells were necessary for tumor suppression, as treatment of B6AF1 effector cells with anti-Thy 1.2 serum abrogated suppression; T cell enrichment by nylon-wool treatment of effector cells increased tumor suppression. Delay in tumor growth was an in vivo phenomenon, for anti-Thy 1.2 serum in AKR hosts abrogated the effect of Thy 1.2 effector cells.

References

Jan 1, 1979·Journal of Immunological Methods·P H Sugarbaker, A E Chang
Jul 15, 1973·International Journal of Cancer. Journal International Du Cancer·D IlfeldN Trainin
Nov 15, 1974·International Journal of Cancer. Journal International Du Cancer·S B HowellL W Llaw
Oct 1, 1973·European Journal of Immunology·M H JuliusL A Herzenberg
Dec 1, 1973·Journal of the National Cancer Institute·A KempB Amos
Dec 1, 1970·Transplantation·G L Irvin, J C Eustace
Jan 29, 1966·Nature·A E Reif, J M Allen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.